Bayer CropScience Ltd

Q4 FY20Fertilizers & Agrochemicals

Bayer CropScience Q4 FY20 earnings call: Revenue & Margins

Q4 FY20 investor presentation: what the company reported on revenue, margins and projects.

Price₹3,736

Market cap₹17.0K Cr

P/E23.2

Updated24 Sept 2026

Read4 min read

Based on Bayer CropScience Ltd's Q4 FY20 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Revenue from Operations for Q4 FY 2019-20: ₹36,094 million, up 14% YoY (₹31,673 million in Q4 FY 2018-19) [Page 8] - Profit Before Exceptional Items and Tax for Q4 FY 2019-20: ₹4,587 million, up 82% EBITDA for Q4 reported at ₹4,587 million, up 82% year-on-year (Page 8).

From Bayer CropScience Ltd's Q4 FY20 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

Revenue from Operations for Q4 FY 2019-20: ₹36,094 million, up 14% YoY (₹31,673 million in Q4 FY 2018-19) [Page 8]
Profit Before Exceptional Items and Tax for Q4 FY 2019-20: ₹4,587 million, up 82% YoY (₹2,522 million in Q4 FY 2018-19) [Page 8]
Proforma FY growth in revenue at 8% and profit at 34% [Page 8]
Sales growth driven by strong market conditions, increased channel penetration, and integration synergies [Pages 13 & 14]
Early onset of farmer purchases for the kharif season reflected in higher April sales [Page 15]

2 more points management made on revenue & sales performance

Profitability & Margins

EBITDA for Q4 reported at ₹4,587 million, up 82% year-on-year (Page 8).
Operating profit before working capital changes for the full year was ₹7,737 million, up ₹2,264 million versus prior year (Page 10).
Profit Before Exceptional Items and Tax for Q4 was ₹7,133 million, up 49% year-on-year (Page 8).

2 more points management made on profitability & margins

See what Bayer CropScience Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The investor presentation does not explicitly mention any capex amounts, capacity expansion projects, or new plant developments with specific details, status, or timelines. Key related points include: - All owned and third-party manufacturing sites and warehouses are operating at high capacity (Page 17). - Owned manufacturing sites are following Bayer Pandemic Preparedness Plan (Page 17).

- No details on new plant constructions, capacity expansion projects, or associated capex amounts are provided. - Integration activities are well on track but specifics on capital expenditure or new facilities are not disclosed (Page 8, 22). Hence, the presentation focuses more on operational continuity, integration progress, and market outlook rather than detailing capex or capacity expansion initiatives.

2 more points management made on capital expenditure plans

Top-ranked in Fertilizers & Agrochemicals

Ranked on what management guided this quarter

5x potential

1Anya Polytech &₹211 Cr

Rev 2Mar 1

2Dharmaj Crop₹998 Cr

Rev 2Mar 2

3₹7.4K Cr

Rev 2Mar 3

4₹5.8K Cr

Rev 2Mar 3

5₹1.3K Cr

Rev 3Mar 1

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The investor presentation does not explicitly mention any fundraising through debt or equity, nor any specific changes in borrowings or net debt. Key relevant points include: - Page 10 shows cash flow overview highlighting net cash from operating activities increased by ₹2,331 million to ₹6,659 million in FY 2019-20. - Net cash used in investing activities reduced significantly by ₹3,858 million, to ₹(289) million. - Net cash used in financing activities slightly decreased by ₹100 million to ₹(1,483) million.

2 more points management made on fundraising & capital structure

See what Bayer CropScience Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report any figures or details related to order book, order inflow, or pending orders. The presentation focuses mainly on: - Financial performance, including revenue, profit, and cash flow. - Business updates such as integration status and market outlook. - COVID-19 impact and management measures. - Employee engagement and stakeholder collaboration.

2 more points management made on order book & pipeline

Bayer CropScience Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.1K Cr, net profit ₹162 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Bayer CropScience Ltd's management said in earlier quarters

Compare:vs Coromandel International Ltd vs Fertilizers & Chemicals Travancore Ltd vs UPL

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Bayer CropScience Ltd Q4 FY20 results?

What is Bayer CropScience Ltd share price analysis?

Bayer CropScience Ltd currently shows a neutral. The stock trades at a P/E of 23.2 with a market cap of ₹16,986 Cr. Investors should review the full earnings analysis for detailed insights.

Is Bayer CropScience Ltd planning capital expenditure?

The investor presentation does not explicitly mention any capex amounts, capacity expansion projects, or new plant developments with specific details, status, or timelines.

Keep Bayer CropScience Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.